Insights

More Articles Back to Article

EU OKs Servier, Taiho's Lonsurf as metastatic gastric cancer monotherapy

Servier and Taiho's Lonsurf, or trifluridine/tipiracil, has been approved by the European Commission as monotherapy for adults with metastatic gastric cancer, including those with gastroesophageal junction adenocarcinoma who received two or more prior treatments. The approval was based on a late-stage trial showing that patients with refractory metastatic gastric cancer who were given Lonsurf had 5.7 months overall survival, compared with 3.6 months OS among those who received placebo. PharmaTimes online (UK) (9/6)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!